CEP
DNLI icon

Chicago Equity Partners’s Denali Therapeutics DNLI Stock Holding History

Chicago Equity Partners’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-78,890
Closed -$1.21M – 889
2019
Q3 		$1.21M Sell
78,890
-38,530
-33% -$736K 0.06% 441
2019
Q2 		$2.44M Buy
+117,420
New +$2.63M 0.11% 273

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Chicago Equity Partners's DNLI Position: Q4 2019 in Review

Chicago Equity Partners sold out of Denali Therapeutics (DNLI) in Q4 2019, closing a stake of 78,890 shares — an estimated $1.21M sold.

Chicago Equity Partners first reported a position in DNLI in Q2 2019 and held it in 2 quarters. The position peaked at $2.44M in Q2 2019. 108 funds tracked by Wall St. Rank hold DNLI as of Q4 2019.

  • Chicago Equity Partners reported no remaining Denali Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Chicago Equity Partners sold 78,890 Denali Therapeutics shares in Q4 2019, an estimated $1.21M.
  • Chicago Equity Partners first reported a position in Denali Therapeutics in Q2 2019 and held it in 2 quarters.
  • Chicago Equity Partners's Denali Therapeutics position peaked at $2.44M in Q2 2019.
  • 108 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2019.

Based on Chicago Equity Partners's 13F filing for Q4 2019, filed 10 Feb 2020.